Innate Pharma (IPHA) Intangibles (2017 - 2023)

Innate Pharma (IPHA) has disclosed Intangibles for 6 consecutive years, with $447591.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Intangibles fell 71.81% year-over-year to $447591.0, compared with a TTM value of $447591.0 through Dec 2023, down 71.81%, and an annual FY2023 reading of $449994.5, down 71.65% over the prior year.
  • Intangibles was $447591.0 for Q4 2023 at Innate Pharma, down from $1.6 million in the prior quarter.
  • Across five years, Intangibles topped out at $107.3 million in Q4 2019 and bottomed at $447591.0 in Q4 2023.
  • Average Intangibles over 4 years is $40.0 million, with a median of $26.1 million recorded in 2022.
  • The sharpest move saw Intangibles grew 11.25% in 2019, then tumbled 96.86% in 2022.
  • Year by year, Intangibles stood at $107.3 million in 2019, then plummeted by 52.9% to $50.6 million in 2021, then crashed by 96.86% to $1.6 million in 2022, then tumbled by 71.81% to $447591.0 in 2023.
  • Business Quant data shows Intangibles for IPHA at $447591.0 in Q4 2023, $1.6 million in Q4 2022, and $50.6 million in Q4 2021.